Skip to main content
. 2013 Oct 4;8(10):e75564. doi: 10.1371/journal.pone.0075564

Figure 1. Samples with SULF2U were more sensitive to cisplatin and those with SULF2M (48.80% vs. 38.15%, P = 0.02, n = 100, t-test); samples with SULF2M were more sensitive to irinotecan than SULF2U (53.61% vs. 40.92%, P = 0.01, n = 100, t-test).

Figure 1

The median is the central line in each box.